Oncology Care Consolidation and the Changing Clinical Trial Environment - Amherst Partners
17646
post-template-default,single,single-post,postid-17646,single-format-standard,bridge-core-1.0.5,ajax_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive

Oncology Care Consolidation and the Changing Clinical Trial Environment


Can robust M&A activity have a direct benefit on cancer treatment? Amherst Partners Healthcare Practice Leader John Patterson speaks with Wes Chapman, Founder and CEO of Verdi Oncology, an innovator in the formation of regional oncology care networks, on how bringing together thought-leading oncology care professionals can accelerate clinical trials for new cancer drugs and treatment protocols, thus fueling improvements in patient care.